BMS’s Mezigdomide Myeloma Data Give Glimpse Of CELMoD Future

Published Phase I/II data for Bristol Myers Squibb Company’s mezigdomide bolster the case for the drug’s activity and safety in heavily pretreated multiple myeloma patients, particularly those who have received prior BCMA-directed therapies. The results also hint at where the drug could end up fitting into treatment, with patients who have failed on BMS’s Pomalyst (pomalidomide) being an attractive target population.

Results of the study of mezigdomide combined with dexamethasone in triple-class refractory patients appeared online 30 August in the New England Journal of Medicine. Mezigdomide is a cereblon E3 ubiquitin ligase modulator (CELMoD) in Phase III development for multiple myeloma; BMS has another CELMoD, iberdomide, in Phase III as well